Biosketch
Björn Frendéus is the CSO of BioInvent, a Swedish Biotech developing antibody-based treatments for cancer immunotherapy. Björn got his PhD studying innate immune responses to microbial infection. Over the past decades, he has developed a strong interest in understanding the complex biology of antibodies and their targeted receptors, applying his knowledge to develop better antibody-based medicines. Björn’s team conceived and developed a function-first platform from which BioInvent’s current pipeline has emerged. The pipeline comprises several first-in-class antibodies to emerging immune checkpoints including the inhibitory Fc gamma receptor FcgRIIB (BI-1206 and BI-1607) and TNFR2 (BI-1808 and BI-1910). BioInvent is closely collaborating on several of its programs with the Cancer Sciences Division in Southampton, UK, where Björn is a visiting professor.
https://www.bioinvent.com